XORTX Therapeutics Files October 2025 Report
Ticker: XRTX · Form: 6-K · Filed: Oct 29, 2025 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
TL;DR
XORTX filed their monthly update, confirming they're a foreign private issuer using Form 20-F.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on October 29, 2025, to report its activities for the month of October 2025. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The report was signed by CEO Allen Davidoff.
Why It Matters
This filing provides an update on XORTX Therapeutics' regulatory reporting status and confirms their adherence to SEC filing requirements as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- October 29, 2025 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the issuer makes or is required to make public in its home country.
Which form does XORTX Therapeutics Inc. use for its annual reports?
XORTX Therapeutics Inc. files its annual reports under cover of Form 20-F.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
The Form 6-K filing was signed by Allen Davidoff, Chief Executive Officer of XORTX Therapeutics Inc.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is October 29, 2025.
What is the standard industrial classification for XORTX Therapeutics Inc.?
The standard industrial classification for XORTX Therapeutics Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-10-29 10:05:24
Filing Documents
- f6k_102925.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-006754.txt ( ) — 12KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: October 29, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated October 29, 2025